Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersSpecialist in Alameda, CA
NPI: 1205937646Primary Employer
Marin Cancer Care, Inc.
marincancercare.com
HQ Phone
Get M.D. Peter's Phone Numberphone_androidMobile
Get M.D. Peter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
CA State Medical License
1976 - 2025
FL State Medical License
1974 - 1989
CA State Medical License
American Board of Internal Medicine
Internal Medicine
Drexel University College Of Medicine
drexel.edu
Medical School
Until 1972
University of Florida College of Medicine Jacksonville
Residency • Internal Medicine
1974 - 1975
Internship • Internal Medicine
1972 - 1973
University of Michigan Health - Sparrow
Residency • Internal Medicine
1973 - 1974
UCSF School of Medicine
medschool.ucsf.edu
Fellowship • Hematology and Medical Oncology
1976 - 1978
Measuring Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice Initiative
Authors: Kristen McNiff, Michael N. Neuss, Joseph O. Jacobson, Peter D. Eisenberg, Pamela Kadlubek, Joseph V. Simone
Publication Date: 2008-08
Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study.
Authors: Poplin, E, Fleming, T, MacDonald, J S, Eisenberg, P, Fisher, R I, Conrad, M E
Journal: Invest New Drugs
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Authors: Lyudmila Bazhenova, Eric Haura, Shirish Gadgeel
Publication Date: 2010-04
Lead Sponsor: Arcus Biosciences, Inc.
Collaborators: Gilead Sciences
Intervention / Treatment: DRUG: Zimberelimab, DRUG: Etrumadenant, DRUG: Domvanalimab
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Laboratory Biomarker Analysis, DRUG: Cyclophosphamide, DRUG: Paclitaxel, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, OTHER: Laboratory Biomarker Analysis, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Ibrutinib, BIOLOGICAL: Rituximab, PROCEDURE: Computed Tomography, PROCEDURE: Bone Marrow Aspiration, DRUG: Bendamustine Hydrochloride